Reviva Pharmaceuticals Holdings, Inc. Marketable Securities, Unrealized Gain (Loss)
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 9-month period ending 2020-11-30, per its 10-Q filed 2021-01-14.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2021-01-14
- Reviva Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2020-11-30 was $0.00.
- Reviva Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2020-08-31 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2020-05-31 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2020-02-29 was $12.07K.
- Reviva Pharmaceuticals Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2020 was $18.71K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 2 month | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 5 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 8 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 11 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|---|---|
| 2020-11-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | $0.00 derived: sum of 2 quarters · filed 2021-01-14 | $0.00 10-Q · filed 2021-01-14 | $12.07K derived: sum of 4 quarters · filed 2021-01-14 | ||||
| 2020-08-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14 | $0.00 10-Q · filed 2020-10-14 | $12.07K derived: sum of 3 quarters · filed 2020-10-14 | -$8.80K derived: sum of 4 quarters · filed 2021-01-14 | ||||
| 2020-05-31 | $0.00 10-Q · filed 2020-07-07 | $12.07K derived: sum of 2 quarters · filed 2020-07-07 | -$8.80K derived: sum of 3 quarters · filed 2021-01-14 | $7.89K derived: sum of 4 quarters · filed 2021-01-14 | ||||
| 2020-02-29 | $12.07K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04 | -$8.80K derived: sum of 2 quarters · filed 2021-01-14 | $7.89K derived: sum of 3 quarters · filed 2021-01-14 | $18.71K 10-K · filed 2020-05-04 | ||||
| 2019-11-30 | -$20.87K 10-Q · filed 2021-01-14 | -$4.18K derived: sum of 2 quarters · filed 2021-01-14 | $6.63K 10-Q · filed 2021-01-14 | |||||
| 2019-08-31 | $16.69K 10-Q · filed 2020-10-14 | $27.51K 10-Q · filed 2020-10-14 | ||||||
| 2019-05-31 | $10.81K 10-Q · filed 2020-07-07 | |||||||
| 2019-02-28 | -$2.58K 10-K · filed 2020-05-04 | |||||||
| 2018-11-30 | -$10.89K 10-Q · filed 2020-01-10 | -$14.95K derived: sum of 2 quarters · filed 2020-01-10 | -$14.95K 10-Q · filed 2020-01-10 | |||||
| 2018-08-31 | -$4.05K 10-Q · filed 2019-10-08 | -$4.05K 10-Q · filed 2019-10-08 | ||||||
| 2018-05-31 | $0.00 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |